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Abstract
We aimed to determine the significance of cytoplasmic antinuclear antibody (ANA) pat-
terns using computer-aided immunofluorescence microscopy in patients with autoim-
mune liver diseases (AILD). ANA staining pattern was identified by treating cultured
human epithelial type 2 (HEp-2) cells with the sera of the patients. Medical records of
patients with suspected AILD who had positive cytoplasmic ANA patterns between Febru-
ary 2017 and November 2019 were retrospectively reviewed for clinical, laboratory, and
immunological data. Cytoplasmic ANA patterns of AILD and non-AILD groups were com-
pared. Further subgroup analysis of patients with AILD who had reticular or speckled
cytoplasmic ANA patterns was conducted. We found that among the 196 patients with
positive cytoplasmic ANA patterns, 113 (57.6%) were diagnosed with AILD. The percent-
age of reticular cytoplasmic pattern was higher in the AILD group than that in the non-
AILD group (64.0% vs. 21.9%, p < 0.001). Furthermore, patients with AILD who exhibited
a reticular ANA pattern demonstrated a higher positive rate for anti-mitochondrial antibod-
ies (66.7% vs. 2.6%, p < 0.001) than those who exhibited the speckled ANA pattern.
Moreover, AILD patients with the reticular ANA pattern displayed a lower positive rate for
anti-smooth muscle antibodies (0% vs. 45%, p < 0.001) and nuclear ANA pattern (73.2%
vs. 97.5%, p = 0.003) than those with the speckled ANA pattern. Therefore, cytoplasmic
ANA patterns could be used to guide AILD characterization in suspected AILD cases,
especially as the reticular ANA pattern is strongly associated with AILD. Thus, it is impor-
tant to check cytoplasmic ANA patterns for AILD evaluation, even when nuclear ANA pat-
terns are negative.
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Introduction
Autoimmune liver disease (AILD) is a rare immune-mediated chronic liver disease with het-
erogeneous clinical characteristics. AILD includes three major disease entities, autoimmune
hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC)
[1]. AIH is characterized by liver inflammation of unknown origin, presence of antinuclear
antibody (ANA) and anti-smooth muscle antibody (SMA), increased IgG levels, and response
to corticosteroids [2]. PBC is characterized by destructive lymphocytic cholangitis and the
presence of anti-mitochondrial antibody (AMA) [3]. PSC is an autoimmune cholestatic liver
disorder that exhibits a characteristic beaded appearance of the intra- and extra-hepatic bile
ducts and is strongly associated with inflammatory bowel disease and cholangiocarcinoma [4].
Some patients exhibit characteristics of both AIH and PBC, thereby comprising a distinct pop-
ulation with the AIH-PBC overlap syndrome [5].
Autoimmune serology has been extensively utilized in AILD diagnosis and characteriza-
tion. In particular, the ANA test has been traditionally used as a screening test, followed by sec-
ondary tests that identify the presence of specific autoantibodies [6]. ANA has been reported
to occur in 50–70% of AIH patients [7]. In PBC, the positivity rate of ANA is about 50%,
whereas that of AMA is 90%, thus showing specificity [8]. ANA prevalence in PSC varies
widely from 8% to 77% [9].
In the clinical setting, the ANA test is typically performed through indirect immunofluores-
cence assays on human epithelial type 2 (HEp-2) cells, following treatment with the sera from
the patients. To mitigate inter-physician heterogeneity in the naming and classification of
ANA staining patterns and to reach an international consensus, the 2015 International Con-
sensus on ANA Patterns (ICAP) workshop classified ANA patterns into three major groups,
nuclear, cytoplasmic, and mitotic patterns. Nuclear patterns include the distinct staining pat-
tern of the nucleoplasm—speckled or homogeneous—and patterns attributed to specific
nuclear subcomponents, i.e., centromere, nuclear dots, nucleolar, or nuclear envelope. Cyto-
plasmic patterns represent staining of the cytoplasm and are subdivided into five different pat-
terns, i.e., fibrillar, speckled, reticular/mitochondrial, polar/Golgi-like, and rods and rings
[10]. These ANA patterns may provide clinically relevant insights into AILD, such as the sus-
pected disease entity and further recommended diagnostic measures [8, 11–13]. Although
ANA positivity plays an important role in AILD diagnosis, the clinical implications of cyto-
plasmic ANA patterns in AILD have not been well defined.
The recent advent of automated, computer-aided immunofluorescence microscopy
(CAIFM) has enabled substantial accumulation of ANA staining data and reassessment of pre-
vious findings. In addition to enabling more valid and reliable pattern classification, CAIFM
allows antibody profiling based on large-scale data on HEp-2 patterns such that ANA patterns
can be employed in clinical decision-making [14]. Therefore, in this study, we aimed to utilize
stored CAIFM ANA data of patients with suspected AILD to determine the significance of
cytoplasmic ANA patterns in AILD.
Materials and methods
Patient selection
We retrospectively reviewed the medical records of patients who were positive for cytoplasmic
ANA staining from the database hosted by the Department of Laboratory Medicine, Severance
Hospital, Seoul, Korea, between February 2017 and November 2019. At the time of testing, cyto-
plasmic ANA was evaluated by indirect immunofluorescence assays on HEp-2 cells, following
treatment with the sera from the patients. We screened 11,067 patients with positive
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cytoplasmic ANA and excluded duplicates and patients below 16 years of age. Of the remaining
7785 patients, we selected 763 patients who were evaluated in the Gastroenterology department.
Among them, we then reviewed 297 patients with suspected AILD and further excluded 101
patients whose ANA image data files were missing. Finally, 196 patients with cytoplasmic ANA
staining were included in this study (Fig 1). Additionally, we examined the diagnoses of the 466
excluded patients evaluated in the Gastroenterology department and selected an additional 89
non-AILD patients with hepatobiliary diseases for comparison of cytoplasmic ANA patterns.
This study was approved by the Institutional Review Board of Severance Hospital and con-
ducted in accordance with the Declaration of Helsinki (IRB approval number: 4-2020-0784).
Considering the retrospective study design, the requirement of informed consent was waived.
Acquisition of clinical and laboratory data
Clinical data including age, sex, and diagnosis were collected. Laboratory data including white
blood cell (WBC) count, alkaline phosphatase (ALP), aspartate aminotransferase (AST),
Fig 1. Flowchart for patient inclusion. ANA, antinuclear antibody; AILD, autoimmune liver diseases.
https://doi.org/10.1371/journal.pone.0244950.g001
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alanine aminotransferase (ALT), γ-glutamyl transferase (GGT), serum albumin, and total bili-
rubin levels obtained within a week from the date of ANA testing were analyzed in this study.
Additionally, treatment status was examined by reviewing electronic medical records. Medica-
tions that the patient had been receiving within 1 year from the date of the ANA test were
noted.
Immunological profile
Immunological tests included the determination of the presence of the following autoantibod-
ies: ANA, AMA, and SMA. ANA immunofluorescence assays were performed on cultured
HEp-2 cells exposed to patient sera using NOVA Lite DAPI ANA Kit (Inova Diagnostics, San
Diego, CA, USA) according to the manufacturer’s specifications. Briefly, the sera of the
patients were diluted 1:80 for screening. The substrate slides with HEp-2 cells were treated
with diluted patient serum samples for 30 min. After the slides were washed with phosphate-
buffered saline (PBS), they were incubated with fluorescein-labeled anti-human IgG conjugate
and DAPI (40-6-diamidino-2-phenylindol) for 30 min. The slides were washed again with PBS
and then covered with coverslips. The slides were evaluated using NOVA View software (ver-
sion 3.6.0.1), and the results were manually reviewed by two experts. The NOVA View soft-
ware could recognize and identify five major nuclear patterns (homogenous, nucleolar,
centromere, nuclear dot, and speckled) and the presence or absence of cytoplasmic patterns.
All image files were stored and could be reviewed at any time. In this study, the stored ANA
image files that exhibited cytoplasmic patterns in suspected AILD patients were recalled and
manually classified into five major cytoplasmic patterns (fibrillar, speckled, reticular, polar/
Golgi-like, and rods and rings). AMA and SMA were tested using the indirect immunofluores-
cence assay (NOVA Lite ANA KSL Kit, Inova Diagnostics). The screening dilution for AMA
and SMA was 1:20. All test slides for AMA and SMA tests were manually analyzed by a labora-
tory medicine specialist using a fluorescence microscope.
Definition of cases
According to the simplified scoring system proposed by the International Autoimmune Hepa-
titis Group (IAIHG), AIH was diagnosed when the pre-treatment simplified score was > 6
and the clinical presentation was consistent with that of AIH [15]. PBC was diagnosed when at
least two of the following criteria were met: (1) biochemical evidence of cholestasis with ALP
elevation, (2) presence of AMA, and (3) compatible liver histopathology in accordance with
the 2009 guidelines of the American Association of the Study of Liver Diseases (AASLD) [16].
Furthermore, patients were diagnosed with AIH-PBC overlap syndrome when both the clini-
cal history and liver biopsy results were typical of the overlap syndrome [17, 18]. Patients were
diagnosed with PSC when the following criteria were met: (1) cholestatic biochemical profile,
(2) compatible cholangiography or liver histopathology, and (3) absence of secondary causes
of cholangitis such as IgG4 disease [19].
Statistical analysis
Continuous variables were presented as the medians with interquartile ranges (IQRs), whereas
categorical variables were expressed as frequencies and percentages. Continuous variables
were compared using the Mann-Whitney U test, whereas categorical variables were compared
using the Chi-square test or Fisher’s exact test, as appropriate. In all statistical analyses, a two-
tailed p-value of< 0.05 was considered significant. Statistical analyses were performed using R
version 3.6.2 (R Foundation for Statistical Computing, Vienna, Austria).
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Results
Baseline characteristics of patients
The demographic and clinical characteristics of 196 patients with suspected AILD included
in this study are shown in Table 1. The median age was 57.96 years, and 75.5% of the
patients were women. Most patients had reticular (51.0%) or speckled (46.4%) cytoplasmic
ANA patterns, while very few patients had fibrillar ANA pattern (2.0%). There were no
cases of polar/Golgi-like or rods and rings patterns. Interestingly, nearly a quarter of the
patients (23.5%) tested negative for nuclear ANA patterns. Among the 196 patients, 113
Table 1. Demographic and clinical characteristics of the enrolled patients with positive cytoplasmic ANA
patterns.
Characteristic All patients (n = 196)




Negative (<1:80) 46 (23.5%)






Rods and rings 0 (0.0%)
Mixed speckled and reticular 1 (0.5%)
Diagnosis
Autoimmune liver disease 113 (100%)
Autoimmune hepatitis (AIH) 64 (56.6%)
Primary biliary cholangitis (PBC) 30 (26.5%)
Overlap syndrome (AIH-PBC) 17 (15.0%)
Primary sclerosing cholangitis (PSC) 2 (1.8%)
Non-autoimmune liver disease 83 (100%)
Drug-induced hepatitis 17 (20.5%)
Non-alcoholic fatty liver disease 16 (19.3%)
Infectious hepatitisa 11 (13.3%)
Chronic hepatitis 11 (13.3%)
Acute hepatitis 9 (10.8%)
Cancerb 6 (7.2%)
Systemic autoimmune disease 5 (6.0%)
Acute cholangitis 3 (3.6%)
Liver cirrhosis 2 (2.4%)
Alcoholic liver disease 2 (2.4%)
Wilson’s disease 1 (1.2%)
Data are presented as the median (interquartile range) or n (%). ANA, antinuclear antibody
aInfectious hepatitis included hepatitis A (n = 2), hepatitis B (n = 5), hepatitis C (n = 1), Epstein-Barr viral hepatitis
(n = 5), and hepatitis due to Clonorchis sinensis (n = 1).
bCancer included cholangiocarcinoma (n = 3), hepatocellular carcinoma (n = 2), and intraductal papillary mucinous
neoplasm (n = 1).
https://doi.org/10.1371/journal.pone.0244950.t001
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(57.6%) exhibited a confirmed diagnosis of AILD, and of those, the majority were diagnosed
with either AIH (56.6%) or PBC (26.5%). Furthermore, 17 (15.0%) patients presented with
overlap syndrome, and the remaining two patients had PSC. Non-AILD cases included
drug-induced hepatitis (20.5%), non-alcoholic fatty liver disease (19.3%), infectious hepati-
tis (13.3%), chronic hepatitis (13.3%), acute hepatitis (10.8%), cancer (7.2%), systemic auto-
immune disease (6.0%), liver cirrhosis (2.4%), alcoholic liver disease (2.4%), and Wilson’s
disease (1.2%).
The treatment status of the patients with AILD within 1 year of the ANA test is presented in
S1 Table. Common AILD treatments used in the patients—corticosteroids, azathioprine,
cyclosporine, and ursodeoxycholic acid (UDCA)—were tabulated. Of note, 53.1% and 26.5%
of the patients with AIH were on corticosteroids and immunosuppressants (azathioprine or
cyclosporine), respectively, whereas only 6.7% of the patients with PBC were on corticoste-
roids. Among patients with AIH-PBC, 47.1% were receiving corticosteroids, and 17.6% were
receiving azathioprine. Most patients with AILD (95.6%) were receiving UDCA.
Cytoplasmic ANA patterns of patients with and without AILD
We compared the cytoplasmic ANA staining patterns of patients with and without AILD. In
the analysis, we also included 89 non-AILD hepatobiliary patients. The representative images
for the speckled and reticular cytoplasmic ANA staining patterns are shown (Fig 2). The pro-
portion of the reticular cytoplasmic ANA pattern was higher in the AILD group than that in
non-AILD group (64.0% vs. 21.9%, p< 0.001) (Table 2).
Cytoplasmic ANA patterns among patients with AILD
We found that among the patients exhibiting the speckled cytoplasmic pattern, a majority
(80%) were diagnosed with AIH (Table 3). Patients with the reticular pattern showed simi-
lar prevalence of AIH and PBC (45.1% and 38.0%, respectively). Furthermore, patients with
the reticular ANA pattern also exhibited higher positivity rate of AMA (66.7% vs. 2.6%,
p < 0.001) and lower positivity rate of SMA (0.0% vs. 45.5%, p < 0.001) compared with
those with the speckled ANA pattern. A lower proportion of patients exhibited positive
nuclear ANA patterns in the reticular group than that in the speckled group (73.2% vs.
97.5%, p = 0.003). In addition, patients in the reticular group showed lower AST (36.0 vs.
110.0 IU/L, p < 0.001), ALT (29.0 vs. 61.0 IU/L, p < 0.001), and total bilirubin (0.80 vs. 1.25
mg/dL, p = 0.002) levels, and higher albumin levels (4.10 vs. 3.70 g/dL, p = 0.005) than
patients in the speckled group. Further analyses were conducted to examine the association
of cytoplasmic ANA patterns with titers and patterns of nuclear ANA (Table 4). Patients in
the reticular group exhibited a higher proportion of nuclear ANA titers (> 1:640) than
patients in the speckled group (50.0% vs. 10.8%, p < 0.001). Patients in the reticular group
also had a higher proportion of the centromere-type nuclear ANA pattern than patients in
the speckled group (20.0% vs. 2.6%, p = 0.031).
Subgroup analysis of patients with the reticular cytoplasmic ANA pattern
We compared AMA positivity among 63 patients with AILD who exhibited the reticular cyto-
plasmic ANA pattern (Table 5). Among the 42 patients who were positive for AMA, more
than half (54.8%) were diagnosed with PBC, followed by AIH (26.2%) and overlap syndrome
(19.0%). Among the 21 patients who were negative for AMA, 14 patients (66.7%) were diag-
nosed with AIH and only 4 patients (19.0%) were diagnosed with PBC.
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Discussion
Nuclear ANA patterns have been utilized to characterize AILD based on its clinical and prog-
nostic relevance [7]. AIH is subclassified into types 1 and 2 (AIH-1 and AIH-2) based on the
serological profile; AIH-1 involves the presence of ANA and SMA, while AIH-2 involves the
Fig 2. Representative images of the cytoplasmic antinuclear-antibody staining pattern in HEp-2 cells by using the sera of AILD or non-AILD patients.
The reticular pattern shows granular and filamentous staining throughout the cytoplasm, whereas the speckled pattern shows fine speckles distributed
throughout the cytoplasm. The reticular (A) and speckled (B) patterns in patients with primary biliary cholangitis, the reticular pattern in a patient with
hepatitis B (C), and the speckled pattern in an osteoarthritis patient (D).
https://doi.org/10.1371/journal.pone.0244950.g002
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presence of anti-liver kidney microsomal antigen type-1 (LKM1) and anti-liver cytosol type 1
(LC1). Approximately 75% of the AIH-1 patients display a homogeneous pattern, and the
remainder display a speckled pattern of nuclear ANA [20, 21]. PBC also is associated with mul-
tiple nuclear dots or rim-like membranous nuclear pattern of ANA, which are very specific
findings (>95%). These two staining patterns provide strong evidence of PBC, which is espe-
cially useful for diagnosing 5–10% of the patients with PBC who are negative for AMA [22,
23]. These staining patterns can be relevant for distinguishing AIH from PBC, because patients
with PBC will very rarely present a homogeneous pattern, and patients with AIH alone will
not typically display PBC-specific staining patterns [20].
Table 2. Cytoplasmic ANA patterns of patients with and without AILD.
Cytoplasmic pattern AILD (n = 111) non-AILD (n = 169) p-value
Reticular 71 (64.0%) 37 (21.9%) < 0.001
Speckled 40 (36.0%) 132 (78.1%)
Data are presented as n (%); p-values were calculated using Fisher’s exact test. ANA, antinuclear antibody; AILD,
autoimmune liver disease
https://doi.org/10.1371/journal.pone.0244950.t002
Table 3. Clinical characteristics of patients with AILD based on the cytoplasmic ANA patterns.
Cytoplasmic pattern
Characteristic Reticular (n = 71) Speckled (n = 40) p-value
Diagnosis
AIH 32 (45.1%) 32 (80.0%) 0.002
PBC 27 (38.0%) 3 (7.5%)
AIH-PBC 11 (15.5%) 4 (10.0%)
PSC 1 (1.4%) 1 (2.5%)
Age (years) 57.50 (51.12–67.58) 58.92 (50.23–67.77) 0.861
Female 60 (84.5%) 33 (82.5%) 0.994
Autoantibodies
AMA positive 42/63 (66.7%) 1/39 (2.6%) < 0.001
SMA positive 0/40 (0.0%) 10/22 (45.5%) < 0.001
ANA positive (�1:80, nuclear) 52/71 (73.2%) 39/40 (97.5%) 0.003
Laboratory findings
WBC count (/μL)a 5.75 (4.83–6.44) 5.25 (3.86–6.64) 0.393
AST (IU/L)b 36.0 (25.0–54.0) 110.0 (45.0–321.0) < 0.001
ALT (IU/L)b 29.0 (17.0–51.5) 61.0 (31.5–226.5) < 0.001
ALP (IU/L)b 129.0 (90.0–221.0) 138.0 (98.5–177.5) 0.956
GGT (IU/L)c 123.0 (57.0–290.5) 159.0 (96.0–272.2) 0.507
Albumin (g/dL)b 4.10 (3.90–4.35) 3.70 (3.05–4.25) 0.005
Total bilirubin (mg/dL)d 0.80 (0.60–1.10) 1.25 (0.80–4.35) 0.002
Data are presented as the median (interquartile range) or n (%); p-values were calculated using the Mann-Whitney U test, the Chi-square test, or Fisher’s exact test, as
appropriate. AILD, autoimmune liver disease; AIH, autoimmune hepatitis; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; ANA, antinuclear
antibody; AMA, anti-mitochondrial antibody; SMA, anti-smooth muscle antibody; WBC, white blood cell; AST, aspartate aminotransferase; ALT, alanine
aminotransferase; ALP, alkaline phosphatase; GGT, γ-glutamyl transferase
aNumber confined to patients who underwent each test (n = 95).
bNumber confined to patients who underwent each test (n = 106).
cNumber confined to patients who underwent each test (n = 89).
dNumber confined to patients who underwent each test (n = 105).
https://doi.org/10.1371/journal.pone.0244950.t003
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In contrast to the robust literature on nuclear ANA patterns, cytoplasmic staining patterns
of ANA have been gaining recognition recently. Cytoplasmic staining may not be reported as
routinely as nuclear staining, but it is now becoming accepted as clinically relevant [24, 25].
Specifically, the speckled cytoplasmic pattern, associated with antigens such as tRNA synthe-
tase, ribosomal P proteins, and signal recognition particle (SRP), is observed in systemic lupus
erythematosus (SLE), anti-synthetase syndrome, interstitial lung disease, and inflammatory
muscle diseases [11]. However, much is yet to be revealed about the prognostic and clinical
role of cytoplasmic ANA patterns.
In this study, among the patients clinically suspected with AILD who exhibited a positive
cytoplasmic ANA pattern, 57.6% were diagnosed with AILD. Therefore, AILD should be sus-
pected in patients with positive cytoplasmic ANA staining pattern, especially when the clinical
presentation aligns with AILD. Of note, the reticular cytoplasmic pattern is a distinct pattern
that correlates with the presence of anti-mitochondrial antibodies. Therefore, if a patient with
unexplained chronic hepatitis exhibits a reticular cytoplasmic ANA pattern, the physician
should suspect AIH or PBC and further test for anti-mitochondrial antibodies. AILD is diffi-
cult to diagnose in its early stages, and is only diagnosed through liver biopsy in many cases
[26]. It should therefore be useful to check the cytoplasmic pattern of ANA—in addition to
Table 4. Nuclear patterns and titers of ANA in patients with AILD based on the cytoplasmic ANA patterns.
Cytoplasmic pattern
Reticular (n = 52) Speckled (n = 39) p-value
ANA titers (nuclear)
�1:640 20/40 (50.0%) 33/37 (89.2%) < 0.001
>1:640 20/40 (50.0%) 4/37 (10.8%)
ANA pattern (nuclear)a
Centromere 10/50 (20.0%) 1/39 (2.6%) 0.031
Homogeneous 13/50 (26.0%) 16/39 (41.0%) 0.203
Speckled 24/50 (48.0%) 29/39 (74.4%) 0.021
Dense fine speckled 1/50 (2.0%) 0/39 (0.0%) NAb
Nuclear dots 8/50 (16.0%) 1/39 (2.6%) 0.083
Nucleolar 1/50 (2.0%) 0/39 (0.0%) NAb
Data are presented as n (%) or n/N (%); p-values were calculated using Fisher’s exact test or the Chi-square test, as
appropriate. ANA, antinuclear antibody; AILD, autoimmune liver disease
aNumber confined to patients who underwent ANA pattern analysis (n = 89).
bNot available
https://doi.org/10.1371/journal.pone.0244950.t004
Table 5. Subgroup analysis of patients with reticular cytoplasmic ANA pattern based on AMA serology.
Diagnosis Reticular cytoplasmic ANA pattern (n = 63) p-value
AMA (+) (n = 42) AMA (-) (n = 21)
PBC 23 (54.8%) 4 (19.0%) 0.003
AIH 11 (26.2%) 14 (66.7%)
AIH-PBC 8 (19.0%) 2 (9.5%)
PSC 0 (0.0%) 1 (4.8%)
Data are presented as n (%); p-values were calculated by Fisher’s exact test. ANA, antinuclear antibody; AMA, anti-
mitochondrial antibody; AIH, autoimmune hepatitis; PBC, primary biliary cholangitis; PSC, primary sclerosing
cholangitis
https://doi.org/10.1371/journal.pone.0244950.t005
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nuclear ANA patterns—to establish a diagnosis. Furthermore, in the current study, 26.8% of
AILD patients with the reticular cytoplasmic ANA pattern showed negative nuclear ANA pat-
tern. We can thus conclude that having negative nuclear ANA does not preclude the patient
from having positive cytoplasmic ANA patterns. Clinicians should consider assessing patients
with suspected AILD for positive cytoplasmic patterns, even when they have negative nuclear
ANA.
Previous studies have reported that the reticular cytoplasmic ANA pattern is associated
with PBC, and in some cases, with systemic sclerosis [11]. In the present study, the reticular
ANA pattern was not only highly associated with PBC but was also observed in patients with
AIH. Moreover, our study showed that 66.7% of the patients with the reticular cytoplasmic
ANA pattern tested positive for AMA; among these patients, 54.8% were diagnosed with PBC.
Among patients with AILD who exhibited a speckled cytoplasmic ANA pattern, only 1 (2.6%)
patient, diagnosed with AIH, tested positive for AMA. Therefore, testing for AMA is the
potential next step for patients exhibiting a reticular cytoplasmic ANA pattern. Interestingly,
none of the patients who exhibited a reticular cytoplasmic ANA pattern was positive for SMA.
Additionally, our study revealed that the levels of ALT, AST, and bilirubin are significantly
lower in AILD patients with reticular cytoplasmic ANA staining than those in patients exhibit-
ing speckled pattern of cytoplasmic ANA staining. Therefore, it is possible that cytoplasmic
ANA pattern might be associated with the clinical presentation or prognosis of AILD.
Furthermore, our study showed that centromere-type nuclear ANA pattern was signifi-
cantly associated with the reticular cytoplasmic ANA pattern. Anti-centromere antibody is an
immunological marker of systemic sclerosis, which is known to be associated with the propen-
sity of developing AILD [27, 28]. Herein, among 11 patients with positive anti-centromere
nuclear pattern, one patient was diagnosed with systemic sclerosis, whereas the rest did not
manifest any clinical signs of systemic sclerosis. Of note, among the remaining ten patients,
four patients had AIH, two patients had PBC, and four patients had AIH-PBC overlap syn-
drome. As only a few reports have suggested an association between the presence of anti-cen-
tromere antibodies and AILD, future studies are warranted to investigate the role of anti-
centromere antibodies in AILD [29–31].
To the best of our knowledge, the current study is the first to investigate the significance of
the reticular cytoplasmic ANA pattern in patients with AILD. By analyzing stored ANA data
collected by CAIFM, we ensured the reliability of cytoplasmic ANA patterns. We only
included patients with AILD who were diagnosed based on the IAIHG and AASLD guidelines,
thereby further validating our results. However, our study has limitations. First, because the
study population consisted only of patients who were evaluated for AILD at a single tertiary
medical center, our study group cannot be assumed to represent the general population with-
out AILD. Second, our study was cross-sectional, not designed to evaluate the prognosis of
AILD, because it requires long term follow-up data. CAIFM is a relatively new technology, and
we only started to use CAIFM for ANA testing in 2017 at our hospital. Therefore, it is still
early to evaluate long term prognosis. In the future, large-scale, longitudinal studies should be
performed to better assess the significance and prognostic value of cytoplasmic ANA patterns
in AILD patients, compared with those in the general population. Additionally, though the
current study assessed the cytoplasmic ANA patterns by exposing HEp-2 cells to patient sera,
further insights could be gained through assessing staining patterns in hepatocytes and cholan-
giocytes, which are more relevant to AILD. Further studies to elucidate the molecular mecha-
nisms underlying the cytoplasmic reticular pattern mediated by autoantibodies is necessary. In
conclusion, cytoplasmic ANA patterns could play a central role in AILD evaluation, and thus,
should be taken into account when considering further diagnostic and therapeutic measures
for AILD.
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